Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.
J Cardiovasc Electrophysiol. 2020 Jan;31(1):70-79. doi: 10.1111/jce.14270. Epub 2019 Nov 20.
Cardiac implantable electronic device (CIED) infections are associated with a high mortality. Our aim was to identify key predictors of survival in patients with CIED infections as to be able to detect high-risk patients and possibly affect modifiable factors.
In this observational study, we collected data from 277 patients with CIED infections treated in our department between 2001 and 2017; predictors of survival were evaluated. The median time since the last CIED procedure was 0.83 years (interquartile range [IQR]: 0.25-3.01), median time since initial CIED implant was 4.79 years (IQR: 0.90-11.0 years). Survival at 30 days was 94.9% (95% confidence interval [CI]: 92.3-97.5) and survival at 1 year was 80.9% (CI: 76.4-85.7). Age (odds ratio [OR]: 1.05, CI: 1.01-1.09; P = .009), end stage renal disease (ESRD) with dialysis (OR: 5.14, CI: 1.87-14.11; P = .001), positive blood cultures (OR: 2.19, CI: 1.08-4.45; P = .030), and thrombocytopenia (OR: 2.3, CI, 1.03-5.15; P = .042) were identified as predictors of death within 1 year of treatment of CIED infection.
Patients with CIED infection with prior ESRD with dialysis or preoperative thrombocytopenia are at an increased risk of 1-year mortality. We suggest that these patients be evaluated critically and resources be allocated to these patients more liberally. A greater understanding of the role of platelets in immunity may improve treatment of advanced infection in the future.
心脏植入式电子设备(CIED)感染与高死亡率相关。我们的目的是确定 CIED 感染患者生存的关键预测因素,以便能够发现高危患者,并可能影响可改变的因素。
在这项观察性研究中,我们收集了 2001 年至 2017 年在我们科室治疗的 277 例 CIED 感染患者的数据;评估了生存的预测因素。自最后一次 CIED 手术后的中位时间为 0.83 年(四分位距[IQR]:0.25-3.01),自首次 CIED 植入的中位时间为 4.79 年(IQR:0.90-11.0 年)。30 天生存率为 94.9%(95%置信区间[CI]:92.3-97.5),1 年生存率为 80.9%(CI:76.4-85.7)。年龄(比值比[OR]:1.05,CI:1.01-1.09;P=0.009)、终末期肾病(ESRD)伴透析(OR:5.14,CI:1.87-14.11;P=0.001)、血培养阳性(OR:2.19,CI:1.08-4.45;P=0.030)和血小板减少症(OR:2.3,CI:1.03-5.15;P=0.042)被确定为 CIED 感染治疗后 1 年内死亡的预测因素。
患有 ESRD 伴透析或术前血小板减少症的 CIED 感染患者 1 年死亡率增加。我们建议对这些患者进行严格评估,并更自由地为这些患者分配资源。对血小板在免疫中的作用有更深入的了解,可能会改善未来对晚期感染的治疗。